Filing Flows

Filing Flows › Companies › Capricor Therapeutics › Cash flow

Capricor Therapeutics cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$35.5M in Q2 2026 · −$115M over twelve months

Operating cash flow−$31.5M
Capital spending−$4.1M
Free cash flow−$35.5M

Analysis

In Q2 2026, Capricor Therapeutics generated −$31.5M of operating cash flow and spent $4.1M on capital projects, leaving free cash flow of −$35.5M. That is $15.1M less than in Q2 2025 (−$20.4M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$104M; the largest uses were other investing ($133M), operating cash flow ($104M), capital spending ($10.9M); besides operations, cash came from other financing ($231M), shares issued ($15.4M); the cash balance fell by $2.3M.

Operating cash flow was −$31.5M against net income of −$40.7M. The largest differences: depreciation & amortization +$562K, prepaid and other assets +$82K, other non-cash +$8K.

Free cash flow

Capricor Therapeutics: free cash flow by quarterCapricor Therapeutics: free cash flow by quarter−$11.7MQ3 2024−$15.3MQ4 2024−$7.3MQ1 2025−$20.4MQ2 2025−$19.7MQ3 2025−$25.2MQ4 2025−$34.4MQ1 2026−$35.5MQ2 2026
Operating cash flow less capital spending.
Capricor Therapeutics: operating cash flow against capital spendingCapricor Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$11.6M$9KQ3 2024−$14.8M$489KQ4 2024−$6.4M$896KQ1 2025−$20.1M$288KQ2 2025−$19.7M$56KQ3 2025−$23.6M$1.7MQ4 2025−$29.3M$5.1MQ1 2026−$31.5M$4.1MQ2 2026
Latest (Q2 2026): Operating cash flow −$31.5M, Capital spending $4.1M.

Capital allocation, year by year

Capricor Therapeutics: where the cash came from (up) and went (down), by fiscal yearCapricor Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY2021: Operating cash flow −$16.8MFY2021: Shares issued $20.2MFY2021: Capital spending −$1.2M$20.2MFY2021FY2022: Operating cash flow $4.9MFY2022: Shares issued $4.9MFY2022: Capital spending −$2.0M$9.8MFY2022FY2023: Operating cash flow −$25.6MFY2023: Shares issued $25.6MFY2023: Capital spending −$1.3M$25.6MFY2023FY2024: Operating cash flow −$40.0MFY2024: Shares issued $153MFY2024: Capital spending −$1.2M$153MFY2024FY2025: Operating cash flow −$69.8MFY2025: Shares issued $249MFY2025: Capital spending −$2.9M$249MFY2025
Over these 5 years operating cash flow totalled −$147M; the largest uses were operating cash flow ($152M) and capital spending ($8.6M). Cash-flow statements as filed.

Where the cash came from and went

Capricor Therapeutics: sources (+) and uses (−) of cash, Q2 2026Capricor Therapeutics: sources (+) and uses (−) of cash, Q2 2026Cash drawn (+) / kept (−)$84.5MOther investing−$44.7MOperating cash flow−$31.5MOther financing−$6.3MCapital spending−$4.1MShares issued$2.1M
Capricor Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Capricor Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Other financing$231MOther investing−$133MOperating cash flow−$104MShares issued$15.4MCapital spending−$10.9MCash drawn (+) / kept (−)$2.3M

From profit to cash

Capricor Therapeutics: net income to operating cash flow, Q2 2026Capricor Therapeutics: net income to operating cash flow, Q2 2026Net income−$40.7MDepreciation & amortization$562KOther non-cash$8KPrepaid and other assets$82KOperating cash flow−$31.5M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$31.5M−$4.1M$2.1M$84.5M−$35.5M
Q1 2026−$29.3M−$5.1M$1.5M$182M−$34.4M
Q4 2025−$23.6M−$1.7M$11.8M−$268M−$25.2M
Q3 2025−$19.7M−$56K$7K$3.7M−$19.7M
Q2 2025−$20.1M−$288K$20K$5.6M−$20.4M
Q1 2025−$6.4M−$896K$50K−$17.5M−$7.3M
Q4 2024−$14.8M−$489K$81.1M$57.1M−$15.3M
Q3 2024−$11.6M−$9K$67.3M−$57.7M−$11.7M

Capricor Therapeutics: income statement and cash flow

Capricor Therapeutics, Q4 2024: revenue $11.1M (-8% year over year), operating margin -69.1%. The chart follows the revenue to costs, profit and cash.

Capricor Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.